A comparison of selected GLP-1-based medicines, not all available formulations. The Wegovy contender covers the 2.4 mg weekly injection, not oral Wegovy or the 7.2 mg HD injection. Rybelsus is included for context as a diabetes medicine, not an approved weight-loss option.
Tirzepatide leads on reported average weight loss, though suitability still depends on individual medical factors and access.
Supplied reviews and medical reporting consistently identify tirzepatide as the strongest current option for average weight reduction, with reported losses up to 22.5%.Prescription required. Use only the formulation and dose prescribed by your clinician. Price and availability vary.
An established weekly injectable weight-management option. This contender specifically covers the 2.4 mg maintenance dose.
Novo Nordisk reports approximately 15% average loss at 68 weeks with Wegovy 2.4 mg injection in a 1,961-person trial excluding type 2 diabetes, alongside diet and activity guidance. Oral Wegovy and HD 7.2 mg have separate trial results.Prescription required. Use only the formulation and dose prescribed by your clinician. Price and availability vary.
A once-daily oral alternative. Suitability depends on medical history, access, and tolerability; this comparison does not establish superiority over other oral treatments.
The FDA approved Foundayo (orforglipron) for adults with obesity, or overweight with a weight-related condition, alongside diet and physical activity. Approval alone does not establish superiority over other oral treatments.Prescription required. Use only the formulation and dose prescribed by your clinician. Price and availability vary.
Liraglutide remains an established weight-management option, but supplied sources place its average weight loss below newer therapies.
Supplied medical guides identify Saxenda as an FDA-approved weight-loss medication with reported average losses in the 5–10% range.Prescription required. Use only the formulation and dose prescribed by your clinician. Price and availability vary.
A type 2 diabetes medicine, not an approved weight-loss treatment. Any prescribing specifically for weight loss is off-label and requires a clinician’s assessment.
Novo Nordisk identifies Rybelsus as a treatment for adults with type 2 diabetes and says it is not for weight loss. Results from other semaglutide brands, doses or trial populations should not be attributed to Rybelsus.Prescription required. Use only the formulation and dose prescribed by your clinician. Price and availability vary.
Three independent write-ins unlock an honorable mention. The 10 strongest active mentions are shown; inactive mentions archive after 12 months. At 25 recent votes, a contender is scored for possible automatic Top 5 promotion.
No honorable mentions yet. Community suggestions appear below while they gather support.
The five criteria create the AI baseline. The community adjustment is then added or subtracted to produce the current published score.
| Criterion | #1Tirzepatide (Zepbound) | #2Semaglutide (Wegovy 2.4 mg injection) | #3Orforglipron (Foundayo) | #4Liraglutide (Saxenda) | #5Semaglutide (Rybelsus) |
|---|---|---|---|---|---|
| 98 | 86 | 72 | 58 | 60 | |
| 94 | 96 | 76 | 91 | 88 | |
| 88 | 88 | 92 | 62 | 84 | |
| 94 | 95 | 93 | 94 | 0 | |
| 78 | 75 | 68 | 72 | 66 | |
| AI baseline scoreWeighted criteria result | 92.6 | 88.7 | 79.5 | 72.2 | 62.0 |
| Community adjustmentVote-share influence | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current published scoreBaseline + community | 93 | 89 | 80 | 72 | 62 |
The five criteria create the AI baseline. The community adjustment is then added or subtracted to produce the current published score.
| Criterion | #1Tirzepatide (Zepbound) | #2Semaglutide (Wegovy 2.4 mg injection) | #3Orforglipron (Foundayo) | #4Liraglutide (Saxenda) | #5Semaglutide (Rybelsus) |
|---|---|---|---|---|---|
| 98 | 86 | 72 | 58 | 60 | |
| 94 | 96 | 76 | 91 | 88 | |
| 88 | 88 | 92 | 62 | 84 | |
| 94 | 95 | 93 | 94 | 0 | |
| 78 | 75 | 68 | 72 | 66 | |
| AI baseline scoreWeighted criteria result | 92.6 | 88.7 | 79.5 | 72.2 | 62.0 |
| Community adjustmentVote-share influence | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current published scoreBaseline + community | 93 | 89 | 80 | 72 | 62 |
Choose any two contenders.
We’ll line up what matters.
Tirzepatide
Semaglutide
GLP-1/GIP dual agonist
GLP-1 receptor agonist
Weekly injection
Weekly injection; 2.4 mg maintenance dose
Up to 22.5% reported average loss
About 15% at 68 weeks in the cited trial; not a guaranteed individual result
Chronic weight management
Chronic weight management
Editorial comparison using weight-loss evidence, convenience, regulatory fit and tolerability. Regulatory fit means approval for weight management for the named brand; Rybelsus receives zero on that criterion. Scores are not clinical effectiveness percentages or a prescribing recommendation.